Method for preventing and/or treating insulin resistance
US9433650B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Aug 30, 2012 |
| Grant date | Sep 6, 2016 |
| Priority date | — |
| Expiry date | Aug 30, 2032 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2035/11
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Described is the use of Eubacterium hallii et rel. and/or Alcaligenes faecalis et rel., as well as pharmaceutical, food, or feed compositions comprising these bacteria as a medicament, in particular, for preventing and/or treating insulin resistance and/or insulin resistance-related complications such as metabolic syndrome, dyslipidemia and type 2 diabetes mellitus, as well as insulin resistance in endocrine diseases (e.g., obese subjects with type 1 diabetes mellitus, Cushing's disease and lipodystrophy syndromes. Also described is a method for preventing and/or treating insulin resistance and/or insulin resistance-related complications such as dyslipidemia and type 2 diabetes mellitus as well as insulin resistance in endocrine diseases (e.g., obese subjects with type 1 diabetes mellitus, Cushing's disease and lipodystrophy syndromes) in a subject in need thereof, the method comprising the step of increasing the level of Eubacterium hallii et rel. and/or Alcaligenes faecalis et rel. in the small intestine.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.